(NASDAQ: LTRN) Lantern Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Lantern Pharma's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast LTRN's revenue for 2026 to be $41,891,164, with the lowest LTRN revenue forecast at $41,891,164, and the highest LTRN revenue forecast at $41,891,164. On average, 1 Wall Street analysts forecast LTRN's revenue for 2027 to be $156,823,330, with the lowest LTRN revenue forecast at $156,823,330, and the highest LTRN revenue forecast at $156,823,330.
In 2028, LTRN is forecast to generate $363,056,751 in revenue, with the lowest revenue forecast at $363,056,751 and the highest revenue forecast at $363,056,751.